CureVac N.V. (CVAC) Q3 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights a strong financial performance, primarily due to a €400 million upfront payment from GSK, resulting in a significant revenue increase and a transition to operating profit. While there are concerns about litigation and R&D investment risks, the overall sentiment is positive due to strong cash position and promising business updates. The Q&A section did not reveal major negative surprises, and the optimistic guidance on oncology and infectious diseases further supports a positive outlook. The stock price is likely to react positively in the short term.
Key Financial Performance
Cash Position €551 million at the end of September 2024, increased from €402.5 million at the end of 2023, primarily due to the €400 million upfront payment from GSK.
Revenue (Q3 2024) €493.9 million, an increase of €477.4 million compared to the same period in 2023, driven by the licensing agreement with GSK.
Revenue (First Nine Months 2024) €520.7 million, an increase of €489.5 million compared to the same period in 2023, primarily due to the license agreement with GSK.
Operating Profit (Q3 2024) €368.4 million, compared to an operating loss of €54 million in Q3 2023, driven by the significant revenue from the GSK agreement.
Operating Profit (First Nine Months 2024) €221.4 million, compared to an operating loss of €186.2 million in the same period in 2023, influenced by the GSK licensing agreement.
Financial Results (Q3 2024) €2.2 million, a decrease of €3.1 million compared to Q3 2023, mainly due to lower interest income on cash investments.
Financial Results (First Nine Months 2024) €8 million, a decrease of €4.7 million compared to the same period in 2023, primarily due to lower interest income.
Pre-tax Profit (Q3 2024) €370.6 million, compared to a pre-tax loss in Q3 2023, significantly impacted by the GSK licensing agreement.
Pre-tax Profit (First Nine Months 2024) €229.4 million, compared to a pre-tax loss in the same period in 2023, driven by the revenue from the GSK agreement.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Cancer Vaccine Program: CureVac disclosed a new cancer vaccine program targeting squamous non-small cell lung cancer, expanding its off-the-shelf cancer vaccine pipeline.
Urinary Tract Infections Program: CureVac launched a new program for urinary tract infections (UTIs), addressing a critical unmet medical need driven by recurring infections and antibiotic resistance.
Licensing Agreement with GSK: CureVac entered a licensing agreement with GSK valued at up to €1.45 billion, including an upfront payment of €400 million, which was fully booked in Q3 2024.
Workforce Reduction: CureVac initiated a corporate redesign including a 30% reduction of its workforce, aimed at reducing costs while maintaining a focus on R&D.
Operational Expenses Reduction: Operational expenses are expected to decrease by over 30% starting in 2025.
Focus on High Value Indications: CureVac is focusing on high value indications in oncology and infectious diseases, with a strategic shift towards innovation and R&D.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Workforce Reduction: CureVac is undergoing a corporate redesign that includes a 30% reduction of its workforce, which may impact employee morale and operational capacity during the transition.
Regulatory Risks: The company is preparing for IND and CTA submissions for new clinical trials, which involves regulatory scrutiny and the risk of delays or rejections.
Supply Chain Challenges: CureVac has terminated all remaining raw material commitments and closed contract manufacturing organizations related to its first-generation COVID-19 vaccine, which may affect future production capabilities.
Competitive Pressures: CureVac faces significant competition in the mRNA technology space, particularly in oncology and infectious diseases, which could impact market share and profitability.
Economic Factors: The ongoing economic environment, including inflation and potential recessionary pressures, could affect funding availability and operational costs.
Litigation Risks: Increased expenses related to litigation to enforce intellectual property rights may pose financial risks and distract from core business activities.
R&D Investment Risks: Higher investments in oncology development programs may not yield expected results, leading to financial losses and impacting future funding for R&D.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Licensing Agreement with GSK: Valued at up to €1.45 billion, including an upfront payment of €400 million, fully booked in Q3 2024.
Workforce Reduction: Approximately 30% reduction of workforce to be completed by the end of 2024.
Pipeline Expansion: New cancer vaccine program targeting squamous non-small cell lung cancer and a new program for urinary tract infections.
Operational Efficiency: Operational expenses expected to decrease by over 30% starting in 2025.
Cash Position: Strong cash position of €551 million at the end of September 2024.
Future Financial Stability: Cash runway into 2028, with a focus on R&D and innovation.
Revenue Expectations: Revenues increased by €477.4 million to €493.9 million for Q3 2024, primarily driven by the licensing agreement with GSK.
Operating Profit: Operating profit of €368.4 million for Q3 2024, compared to an operating loss of €54 million in Q3 2023.
Clinical Development Timeline: Expect to start Phase I trials for new programs in 2025 and 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Upfront Payment from GSK Licensing Agreement: €400 million upfront payment received from GSK, fully booked in Q3 2024.
Total Cash Position: CureVac reported a strong cash position of €551 million at the end of September 2024.
Revenue Increase: Revenues increased by €477.4 million to €493.9 million for Q3 2024, primarily driven by the GSK licensing agreement.
Operating Profit: Operating profit was €368.4 million for Q3 2024, compared to an operating loss of €54 million for the same quarter in 2023.
Future Financial Stability: CureVac anticipates a substantial increase in operating expenses by over 30% starting in 2025, including a €25 million reduction in personnel costs.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you discuss your thoughts about business opportunity, licensing opportunity outside of the mRNA?
A:We stay very focused on oncology and infectious diseases, with collaborations with GSK and MD Anderson. We are looking for new opportunities within these areas to strengthen our portfolio.
Q:Can you discuss the litigation account update?
A:The U.S. Court case is scheduled for March 2025. We are preparing for this, but have no further updates at this time.
Q:Can you share any commentary and plans for developing a combo vaccine for flu COVID?
A:This question should ideally be addressed by GSK. We believe a combination vaccine would be convenient and promising. Phase I study starts now, with data readout expected next year.
Q:Can you provide reasoning on selecting lung cancer as the new indication?
A:The selection is based on scientific data and the need for coverage of novel antigens in squamous non-small cell lung cancer.
Q:Can you say something regarding patent litigation on the U.S. front, on the Europe front?
A:In Europe, litigation is ongoing on a case-by-case basis. We expect further rulings in the second quarter of next year.
Q:Can you comment on the prior protein-based program that didn't move forward?
A:The prior program was not discussed in detail, but we are confident in our current approach with validated antigens.
Q:How do you believe your approach could be better than the glycoconjugate program in Phase III?
A:Our mRNA approach shows superior immunogenicity and targets both humoral and cellular responses.
Q:How should we think about the translation towards tumor response based off the data for the GBM program?
A:We need more data from our extension cohort to correlate immunologic response with clinical benefit.
Q:What are the indications of most interest for the overall off-the-shelf program?
A:We are focusing on squamous non-small cell lung cancer and are conducting a strategic review for other indications.
Q:Review of Unclear Management Responses
A:Management did not provide a direct answer regarding the specifics of the litigation updates, particularly in Europe, where they mentioned it would be an ongoing process without clear timelines. Additionally, the response about the prior protein-based program lacked clarity on why it didn't move forward.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Axel
CVGBM
Europe
FimH
MD
PFS month
Phase II
Phase III
Phase patient
UPEC
UTIs
agreement GSK
bacteria
bladder
cell lung
coli
development effort
differentiator
disease program
dose confirmation
enrollment
licensing agreement
litigation
lung cancer
nanoparticle
oncology disease
oncology shelf
patent
patient cell
payment
personnel
population
precision
program candidate
program cell
protein vaccine
readout
reduction
serum
shelf program
tract infection
urine
CVAC Transcript
CureVac N.V. (NASDAQ:CVAC) Q4 2024 Earnings Call Transcript
Positive4-12
The earnings call indicates a significant improvement in financial performance, with a shift from operating losses to profits, and strong revenue growth due to a new partnership with GSK. Despite a slight EPS miss, the cash position is strong, and the company is strategically focusing on oncology. The Q&A section reveals cautious optimism in clinical trials and regulatory interactions, with no major negative surprises. Overall, the financial health and strategic focus on partnerships suggest a positive market reaction.
CureVac N.V. (CVAC) Q4 2024 Earnings Call Transcript
Positive4-10
The earnings call highlights strong financial performance with a significant increase in full-year revenue due to a new GSK licensing agreement, a substantial upfront payment, and improved operating profit. The Q&A section indicates management's cautious optimism, and despite some vague responses, they reaffirm a strong cash position and financial runway. The strategic restructuring and workforce reduction pose some risks, but the overall sentiment is positive due to the financial improvements and strategic partnerships.
CureVac N.V. (CVAC) Q3 2024 Earnings Call Transcript
Positive11-12
The earnings call highlights a strong financial performance, primarily due to a €400 million upfront payment from GSK, resulting in a significant revenue increase and a transition to operating profit. While there are concerns about litigation and R&D investment risks, the overall sentiment is positive due to strong cash position and promising business updates. The Q&A section did not reveal major negative surprises, and the optimistic guidance on oncology and infectious diseases further supports a positive outlook. The stock price is likely to react positively in the short term.
CureVac N.V. (CVAC) Q4 2023 Earnings Call Transcript
Unknown4-24
The earnings call reveals mixed signals: a strong cash position and increased Q4 revenue, but a full-year revenue decline and increased operating loss. The Q&A highlights uncertainties in vaccine timelines and oncology trials. Despite efficiency gains, cost management challenges persist. No guidance was provided, which typically concerns investors. Without a market cap, a neutral prediction is prudent, balancing positive cash flow extensions and strategic risks.
CVAC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
